On Oct. 6, 2020, AIM ImmunoTech announced that it had received Institutional Review Board approval for the expansion of the AMP-511 Expanded Access Program clinical trial for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome to include patients previously diagnosed with SARS-CoV-2, but who still demonstrate chronic fatigue-like symptoms. Patients in the trial are treated with AIM’s flagship pipeline drug Ampligen.